Commercial at-home gut microbiome tests are becoming more common among patients, but gastroenterologists and microbiome researchers caution that their clinical value remains unproven. Reports often classify microbiomes as “healthy” or “imbalanced” and recommend dietary changes or supplements, despite limited evidence that these findings provide meaningful medical guidance.
A 2026 study published in Communications Biology compared seven commercial testing companies using identical stool samples and found substantial disagreement in the organisms identified and the interpretation of results. The variability between providers was comparable to biological differences between individual donors. Differences in sample collection, storage, processing, sequencing methods, and analysis further limit consistency across tests.
An international consensus statement published in The Lancet Gastroenterology & Hepatology concluded that commercial microbiome testing lacks proven clinical value for most patients. Wider clinical adoption would require standardized laboratory methods, validated definitions of clinically meaningful abnormalities, and evidence that treatment decisions based on results improve patient outcomes. Experts also warn that test-driven recommendations may lead to unnecessary dietary restrictions or supplement use.

